Opko Health Inc (OPK)

[tomsylver]

February 26, 2015
4Kscore Might Reduce Unnecessary Prostate Biopsies ( http://www.cancertherapyadvisor.com/4kscore-identify-high-grade-prostate-cancer-unnecessary-testing/article/400479/ )

ORLANDO—The 4Kscore, an algorithmic analysis of data from a blood test that combines four kallikrein assays with clinical information to identify the probability of high-grade prostate tumors, could dramatically reduce the number of unnecessary prostate biopsies, according to a multi-institutional prospective study (Abstract 1) presented during the 2015 Genitourinary Cancers Symposium. ( http://www.cancertherapyadvisor.com/genitourinary-cancers-symposium-2015/section/4812/ ) (1)

“The 4Kscore demonstrated excellent accuracy in detecting high-grade prostate cancer,” reported lead study author Sanoj Punnen, MD, of the Sylvestor Comprehensive Cancer Center and Department of Urology, University of Miami in Miami, FL. “It is a useful tool in selecting men who are likely to have high-grade disease and most likely to benefit from a prostate biopsy versus those men with no cancer or indolent cancer.”

Prostate cancer screening is associated with improved cancer-specific mortality “but comes at a high cost,” Dr. Punnen noted. “Saving one man's life requires that 1,068 men be screened and 48 undergo treatment…. Many men will have to undergo unnecessary testing,” he said. “Biopsy entails significant risks of urinary incontinence and emotional stress.”

The 4Kscore has been “well validated in multiple retrospective European cohorts,” Dr. Punnen reported, but it has not previously been tested prospectively or in the United States.

A total of 1,012 men scheduled for prostate biopsy were enrolled at 26 United States cancer centers during 2013 and 2014.

High-grade prostate cancer was detected in 231 (22.8%) study participants. The 4Kscore exhibited “near-perfect calibration, with the predicted probability of high-grade cancer being similar to the observed [rate],” Dr. Punnen reported.

“The 4Kscore demonstrated higher discrimination then the popular Prostate Cancer Prevention Trial Risk Calculator (PCPTRC) (area under curve 0.82 versus 0.74),” Dr. Punnen reported. “In addition, the 4Kscore displayed a higher net benefit by decision curve analysis than the PCPTRC and standard of care at all threshold probabilities used in common clinical practice. For example, if a 9% probability of high-grade cancer was used as a threshold for biopsy of the prostate, 434 (43%) unnecessary biopsies could have been avoided, while delaying diagnosis of only 24 (2.4%) high-grade cancers.”

The risk of missing a high-grade cancer was less than 1%, he noted.

These results suggest “drastic reductions” in the number of biopsies would result from widespread use of the 4KScore, he concluded.

Reference

Punnen S, Sjoberg D, Zappala SM, et al. A multi-institutional prospective trial in the United States to confirm the 4Kscore identification of men with high-grade prostate cancer. 2015 Genitourinary Cancers Symposium. Abstract 1.

Biography

Dr. Sanoj Punnen is an expert in Urologic Oncology. He provides specialty care for patients with urologic malignancies including prostate, renal, bladder, and testes cancer. He utilizes both open and minimally-invasive procedures, including robotic surgery, to suit the individual needs of each patient.

Dr. Punnen completed his Medical Degree at Queen’s University in Ontario, Canada and went on to complete a residency in Urology at the University of Toronto in Toronto, Canada. He subsequently completed a fellowship in Urologic Oncology at the University of California, San Francisco with a focus on robotic surgery. While there he also attained a Masters in Advanced Sciences in Clinical Research.

Dr. Punnen has conducted research on many aspects of urologic malignancy. He has an interest in cancer detection, risk-stratification, prognosis and bio-markers. He also has an interest in outcomes research focusing on both cancer control and quality of life outcomes. He has published several scientific articles on these topics and has presented his work at numerous meetings internationally.

Dr. Punnen has a strong dedication to patient care and uses both his clinical and research experience to bring the most innovative care to meet the needs of each individual patient.

Published on Feb 26, 2015
Dr. Sanoj Punnen discusses his multi-institutional trial results on how the 4Kscore can accurately identify high-grade prostate cancer. He presented his findings at ASCO's Genitourinary Cancers Symposium 2015 meeting. Click Here For External Video Link (

)